Becton Dickinson
Becton Dickinson Fiscal Q4 Revenues Rise 7 Percent
The medical technology and diagnostics firm saw a 3 percent increase in fiscal year 2023 revenues, despite an 8 percent decline in its life sciences business.
Becton Dickinson, Navigate BioPharma Collaborate on Flow Cytometry Companion Diagnostics Development
The partners will offer their combined expertise to biopharma companies developing diagnostics and clinical decision-making tools.
Abbott Laboratories, Beckman Coulter, Siemens Healthineers, Roche Gain FDA Clearances in July
Beckman Coulter's DxC 500 AU Clinical Chemistry Analyzer and Siemens Healthineers' Atellica CI Analyzer are among the 510(k) clearances issued in July.
Becton Dickinson Q3 Base Revenues Grow 7 Percent as Life Sciences Segment Remains Flat
Within BD Life Sciences, growth in BD Biosciences was offset by a decline in COVID-related testing in Integrated Diagnostics Solutions.
BD Gains FDA Clearance for Combination COVID-19, Flu, RSV Molecular Test
The RT-PCR-based BD Respiratory Viral Panel for BD Max received a CE mark in 2022 and FDA Emergency Use Authorization earlier this year.